Chad Reiter is a Board-Certified (DABT) Toxicologist at NAMSA. With over 7 years of experience in the medical device industry, his previous positions at NAMSA include Medical Research Manager (Study Director) and Senior Scientist. Chad’s expertise includes physiology, cellular biology, device biocompatibility, toxicology, and in vitro and in vivo test methods. He obtained his bachelor’s degree in Biochemistry from North Central College and his PhD in Physiology from Penn State University. Before joining NAMSA, Chad was a post-doctoral fellow at the National Institute of Health (NIH) and a Commissioner’s Fellow with the FDA. While at the FDA, Chad investigated the use of blood substitutes in various therapies. His research investigated oxygen delivery following hemoglobin modifications and the toxicity of interacting with cell-free hemoglobin.

CORE COMPETENCIES

• Preparing risk assessments, evaluation plans, and reports in compliance with ISO 10993-1, ISO 10993-17, and ISO 14971, for submissions to the FDA and other regulatory agencies
• Evaluating and summarizing biocompatibility and general toxicology data ensuring compliance with the relevant regulatory requirements and standards
• Working knowledge of the FDA, EU MDD, and other global medical device regulations and biologics regulations, including ISO 10993 series and ISO 14971
• Ensuring biocompatibility studies comply with most recent regulatory requirements
• Providing technical support to laboratory staff
• Advising clients on technical issues related to biocompatibility and material characterization
• Performing biocompatibility gap analysis as regulations are updated
• Study Director of GLP-compliant preclinical safety studies for medical devices (ISO 10993 series)
• Directing analytical chemistry studies to determine leachables from product components (ISO 10993 series and ISO/TS 21726)

PUBLICATIONS 

• Ticar BF et al (2020) Biocompatibility and Structural Characterization of Glycosaminoglycans Isolated From Heads of Silver-Banded Whiting (Sillago Argentifasciata Martin & Montalban 1935). Int J Biol Macromol, 151, 663-676.
• Barber AJ et al. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt mediated mechanism that reduces the activation of caspase-3.  J Biol Chem, 276, 32814-32821, 2001.
• Reiter CEN, and Gardner TW. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy.  Prog Retinal and Eye Res, 22, 545-562, 2003.
• Reiter CEN et al. Characterization of insulin signaling in rat retina in vivo and ex vivo.  Am J Physiol Endocrinol Metab, 285, E763-E774, 2003.
• Bronson SK, Reiter CEN, and Gardner TW. An eye on insulin.  J           Clin Invest, 111, 1817-1819, 2003.
• Wu X, Reiter CEN, Antonetti DA, Kimball SR, Jefferson LS, and Gardner TW. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner.  J Biol Chem, 279, 9167-9175, 2004.
• Barber AJ et al. The Ins2^Akita mouse as a model of early retinal complications in diabetes.  Invest Ophthalmol Vis Sci, 46, 2210-2218, 2005.
• Reiter CEN, Wu X, Sandirasegarane L, Nakamra M, Gilbert KA, Singh RSJ, Fort PE, Antonetti DA, and Gardner TW. Diabetes reduces basal insulin receptor signaling: reversal with systemic and local insulin.  Diabetes, 55, 1148-1156, 2006.
• Chen H, Lin S, Li Y, Reiter CEN, Ver MR, and Quon MJ. DHEA stimulates phosphorylation of FoxO1 in vascular endothelial cells via PI3-kinase- and protein kinase A-dependent signaling pathways to regulate ET-1 synthesis and secretion.  J Biol Chem, 283, 29228-29238,
• Reiter CEN, Kim JA, and Quon MJ. The green tea polyphenol EGCG reduces ET-1 expression and secretion in vascular endothelial cells: roles from AMPK, Akt, and FOXO1.  Endocrinology, 151, 103-114, 2010.
• Baek JH, Reiter CEN, Manalo DJ, Buehler PW, Hider RC, Alayash AI. Induction of hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the hydroxypyridinone, CP94.  Biochim Biophys Acta, 1809, 262-268, 2011.
• Fort PE et al. Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced cell death: evidence for retinal insulin resistance. PLoS One, 6, e26498, 2011.
• Pullikotil P, Chen H, Muniyappa R, Greenberg CC, Yang S, Reiter CEN, Lee JW, Chung JH, and Quon MJ. Epigallocatechin gallate induces expression of heme oxygenase-1 in endothelial cells via p38 MAPK and Nrf-2 that suppresses proinflammatory actions of TNF-α.  J Nutr Biochem, 23, 1134-1145, 2012
• Reiter CEN and Alayash AI. Effects of carbon monoxide (CO) delivery by a CO donor or hemoglobin on vascular hypoxia inducible factor 1α and mitochondrial respiration.  FEBS Open Bio, 2, 113-118, 2012.